Safety of beta-blocker discontinuation after acute coronary syndromes with preserved or mildly reduced left ventricular ejection fraction: a target trial emulation from a real-world cohort.

MLA

Johner, Nicolas, et al. “Safety of Beta-Blocker Discontinuation after Acute Coronary Syndromes with Preserved or Mildly Reduced Left Ventricular Ejection Fraction: A Target Trial Emulation from a Real-World Cohort.” European Journal of Preventive Cardiology, Oct. 2024. EBSCOhost, https://doi.org/10.1093/eurjpc/zwae346.

APA

Johner, N., Branca, M., Carballo, D., Baggio, S., Nanchen, D., Tessitore, E., Räber, L., Lüscher, T. F., Matter, C. M., Windecker, S., Rodondi, N., Mach, F., & Gencer, B. (2024). Safety of beta-blocker discontinuation after acute coronary syndromes with preserved or mildly reduced left ventricular ejection fraction: a target trial emulation from a real-world cohort. European Journal of Preventive Cardiology. https://doi.org/10.1093/eurjpc/zwae346

Chicago

Johner, Nicolas, Mattia Branca, David Carballo, Stéphanie Baggio, David Nanchen, Elena Tessitore, Lorenz Räber, et al. 2024. “Safety of Beta-Blocker Discontinuation after Acute Coronary Syndromes with Preserved or Mildly Reduced Left Ventricular Ejection Fraction: A Target Trial Emulation from a Real-World Cohort.” European Journal of Preventive Cardiology, October. doi:10.1093/eurjpc/zwae346.